Shares of PMGC Holdings Inc. (NASDAQ: ELAB) experienced a significant surge in premarket trading today, climbing 97.47% to $3.91. This upward trajectory follows the announcement that Northstrive Biosciences Inc., a subsidiary of PMGC, has been invited to present at a prestigious symposium hosted by the UCLA Metabolism Theme.
A UCLA Symposium on New Approaches to Obesity
“Anti-Obesity Treatments: Challenges and Emerging Solutions,” the symposium’s theme, is being coordinated by the UCLA Metabolism Theme, a program of the UCLA David Geffen School of Medicine.
Through the integration of fundamental science, clinical practice, and industrial partnership, this initiative promotes multidisciplinary metabolism research. To address the intricacies of the available weight reduction treatments, the timely event brings together top physicians, researchers, medication developers, and investors with expertise in obesity.
Northstrive Biosciences to Present Innovative Treatment
Northstrive Biosciences has been selected to present its lead asset, EL-22, a novel therapeutic leveraging a first-in-class engineered probiotic approach. This innovative treatment aims to mitigate muscle loss, a significant concern associated with many weight loss interventions, particularly GLP-1 receptor agonists.
These agonists, while effective in promoting weight loss, often lead to a substantial loss of lean muscle mass, a side effect currently lacking effective countermeasures. Studies indicate that between 30% and 50% of weight lost through GLP-1 therapy can be attributed to muscle loss.
Addressing the Critical Issue of Muscle Loss in Weight Management
The symposium provides a crucial platform for addressing the challenges posed by muscle and bone loss associated with current obesity treatments. ELAB’s EL-22 offers a potential solution by targeting this critical gap in existing therapies.
This groundbreaking approach represents a potential paradigm shift in weight management, offering a combined therapy with GLP-1 receptor agonists to preserve muscle mass during weight loss.
PMGC-subsidiary anticipates engaging with key opinion leaders, investors, and established pharmaceutical companies within the obesity sector, further solidifying its presence in this rapidly evolving field.